Unity Biotechnology and Mammoth Biosciences are bpth turning toward cost-saving measures, prompting layoffs at both companies ...

Johnson & Johnson bought the full rights to a rare disease gene therapy a few years ago, but now the Big Pharma may be ...

Deerfield Management has unveiled the third installment of its healthcare innovations fund, earmarking more than $600 million ...

The Jewel wearable cardioverter defibrillator system can be worn during sleep and showers, with its low-profile and ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after reporting what one analyst deems “impressive” overall survival data. | ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. | Recursion is ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for.

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...